Regression of mucosal melanoma following intralesional talimogene laherparepvec (T‐VEC) injection in combination with immunotherapy

Drescher, Christina; Drexler, Konstantin; Hilber, Hermann; Schmidt, Bárbara; Haferkamp, Sebastian

doi:10.1111/ddg.13763

Cited by 3 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Drescher et al. reported on a patient with maxillary sinus mucosal melanoma where T-VEC injections were utilized to treat disease recurrence post surgical resection and radiation therapy while on maintenance immunotherapy with nivolumab [ 12 ]. Though both patients displayed significant response in local disease with the T-VEC injections, the patients had also received immunotherapy preceding the T-VEC therapy.…”

Section: Discussionmentioning

confidence: 99%

Local intralesional talimogene laherparepvec therapy with complete local response in oral palatine mucosal melanoma: a case report

Chitnis,

Seim,

Kendra

2024

J Med Case Reports

View full text Add to dashboard Cite

Background Mucosal melanoma, an aggressive type of malignancy different from the cutaneous melanomas commonly seen in the head and neck region, represents < 1% of all malignant melanomas. The pathogenesis of mucosal melanoma is unknown. Targetable mutations commonly seen in cutaneous melanoma, such as in the BRAF and NRAS genes, have a lower incidence in mucosal melanoma. Mucosal melanoma carries a distinct mutational pattern from cutaneous melanoma. Surgery with negative margins is the first-line treatment for mucosal melanoma, and systemic therapy is not well defined. Talimogene laherparepvec, an oncolytic viral immunotherapy, is United States Food and Drug Administration approved for the treatment of advanced malignant cutaneous melanoma, with local therapeutic benefits. Mucosal melanoma was initially excluded from talimogene laherparepvec’s initial phase III clinical trial. Case presentation We present the case of a white female patient in her 40s with past medical history of systemic lupus erythematous, scleroderma, and estrogen-receptor-positive invasive ductal breast carcinoma. Following a bilateral mastectomy, the patient was found to have BRAF-negative mucosal melanoma of her hard palate with a soft palate skip lesion. Owing to the presence of a skip mucosal lesion as well as the anticipated defect and need for free-flap reconstructive surgery, nonsurgical management was considered. The patient was referred to medical oncology, where—based on the patient’s complicated medical history and the risk of immunotherapy possibly worsening her prior autoimmune diseases—local talimogene laherparepvec injections were chosen as the primary therapy for her mucosal lesions. Though talimogene laherparepvec is approved for the treatment of cutaneous melanoma, there are limited data available on the use of talimogene laherparepvec in mucosal melanomas. Conclusion The patient had a complete local tumor response at both the primary lesion as well as the skip lesion with the local injections. She had no side effects and maintained a high quality of life during treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Local intralesional talimogene laherparepvec therapy with complete local response in oral palatine mucosal melanoma: a case report

Chitnis,

Seim,

Kendra

2024

J Med Case Reports

View full text Add to dashboard Cite

show abstract

Talimogene laherparepvec

2019

Reactions Weekly

View full text Add to dashboard Cite

Development and application of oncolytic viruses as the nemesis of tumor cells

et al. 2023

View full text Add to dashboard Cite

Viruses and tumors are two pathologies that negatively impact human health, but what occurs when a virus encounters a tumor? A global consensus among cancer patients suggests that surgical resection, chemotherapy, radiotherapy, and other methods are the primary means to combat cancer. However, with the innovation and development of biomedical technology, tumor biotherapy (immunotherapy, molecular targeted therapy, gene therapy, oncolytic virus therapy, etc.) has emerged as an alternative treatment for malignant tumors. Oncolytic viruses possess numerous anti-tumor properties, such as directly lysing tumor cells, activating anti-tumor immune responses, and improving the tumor microenvironment. Compared to traditional immunotherapy, oncolytic virus therapy offers advantages including high killing efficiency, precise targeting, and minimal side effects. Although oncolytic virus (OV) therapy was introduced as a novel approach to tumor treatment in the 19th century, its efficacy was suboptimal, limiting its widespread application. However, since the U.S. Food and Drug Administration (FDA) approved the first OV therapy drug, T-VEC, in 2015, interest in OV has grown significantly. In recent years, oncolytic virus therapy has shown increasingly promising application prospects and has become a major research focus in the field of cancer treatment. This article reviews the development, classification, and research progress of oncolytic viruses, as well as their mechanisms of action, therapeutic methods, and routes of administration.

show abstract

Regression of mucosal melanoma following intralesional talimogene laherparepvec (T‐VEC) injection in combination with immunotherapy

Cited by 3 publications

References 7 publications

Local intralesional talimogene laherparepvec therapy with complete local response in oral palatine mucosal melanoma: a case report

Local intralesional talimogene laherparepvec therapy with complete local response in oral palatine mucosal melanoma: a case report

Talimogene laherparepvec

Development and application of oncolytic viruses as the nemesis of tumor cells

Contact Info

Product

Resources

About